SALT LAKE CITY, Feb. 3, 2012 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and distinct mechanisms of action, today announced it will hold a conference call on Thursday, February 9, 2012 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for its second fiscal quarter 2012 ended December 31, 2011.
The conference call will be hosted by Robert Lollini, President and Chief Executive Officer, and Andrea Kendell, Chief Financial Officer.
To participate, please dial (877) 312-5447 (U.S.) or (253) 237-1129 (International); Conference ID: 49381168. To access the live webcast, please visit the Investor Relations section on the corporate website at www.myrexis.com.
A replay of the conference call will be available beginning February 9, 2012 at 7:30 p.m. ET (4:30 p.m. PT) and ending on March 9, 2012 by dialing toll-free in the U.S. (855) 859-2056 or (800) 585-8367 and (404) 537-3406 for international callers, Conference ID: 49381168. A replay of the webcast will also be archived on the corporate website for one month, through March 9, 2012.
About Myrexis, Inc.
Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.
Additional information about Myrexis is available through its corporate website, www.myrexis.com.
The Myrexis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9929